Diagnostic Efficiency With Magnetic Resonance Imaging-targeted Biopsy Compared to Standard Transperineal Ultrasound-guided Biopsy in Biopsy-naïve Suspicious Prostate Cancer Patients: A Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Neoplasm
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Detection rates of clinically significant PCa
- Last Updated
- 6 years ago
Overview
Brief Summary
This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of mpMRI-targeted biopsy compared to transperineal standard biopsy in men with clinical suspicion of prostate cancer who had no prior prostate biopsy.
Detailed Description
Prostate biopsy with multiple samples using a standardized template (standard biopsy, SB) under transrectal ultrasound (TRUS) guidance is the current standard diagnostic approach in suspicion of prostate cancer (PCa). However, many biopsies are unnecessary or cannot detect clinically significant PCa (csPCa). With the introduction of multiparametric magnetic resonance imaging (mpMRI) of the prostate and the improvement for PCa detection and localization, an alternative procedure, known as MRI-targeted biopsy (TB), has been shown comparable or even higher detection rates of csPCa compared to TRUS-biopsy (SB). This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of TB compared to SB (transperineal) in men referred with clinical suspicion of prostate cancer who have had no prior prostate biopsy.
Investigators
Hongqian Guo
Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Eligibility Criteria
Inclusion Criteria
- •Men more than 18 years old with clinical suspicion of prostate cancer;
- •Serum PSA ≤ 20 ng/ml within the previous 3 months;
- •Suspected stage ≤ T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months;
- •No evidence of PSA increase by noncancerous factors, such as catheterization, bladder stones, or urinary tract infection including bacterial prostatitis;
- •mpMRI PI-RADS V2 score 4 or 5；
- •Able to provide written informed consent.
Exclusion Criteria
- •Prior prostate biopsy or prostate surgery;
- •Prior treatment for prostate cancer;
- •Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated glomerular filtration rate ≤ 50mls/min);
- •Contraindication to prostate biopsy.
Outcomes
Primary Outcomes
Detection rates of clinically significant PCa
Time Frame: 30 days post biopsy
Clinically significant prostate cancer is considered as: biopsy Gleason score ≥3+4 or maximum cancer core length ≥5 mm.
Secondary Outcomes
- Proportion of men undergoing radical prostatectomy who have Gleason grade upgrading(90 days post-biopsy)
- Detection rates of clinically insignificant PCa(30 days post biopsy)
- Biopsy-related adverse events(30 days post biopsy)